Head-To-Head T2 Diabetes Drug Study: Victoza Outperformed Januvia
By Mike Boyle

Injections of Danish drug maker Novo Nordisk`s new product Victoza worked better at controlling blood glucose levels in people with type 2 diabetes than did Merck & Co.`s orally-taken drug Januvia, according to results of a head-to-head study recently published in the Lancet journal.

According to researchers who conducted the 26-week study in people with type 2 diabetes who had not responded adequately to the older drug metformin, 1.8 milligrams of Victoza (liraglutide), lowered levels of HbA1c - a standard blood measure that is indicative of a patient`s glucose levels - by 1.5 percentage points against 0.9 percent for Januvia (sitagliptin).

Both Victoza and Januvia increase secretion of the hormone insulin, which helps lower blood sugar levels, and reduce secretion of the hormone glucagon which prevents blood sugar levels rising again.

The lower dose of 1.2 mg of Victoza cut HbA1C by 1.2 points.

The study was funded by Novo Nordisk.

Read a summary of the study here.

 

Want to comment on this story? If you are a registered member of DiabetesCare.net, click here.

Register for your free membership to DiabetesCare.net here.

 

 

Originally posted April 23, 2010.